Concepts (207)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cholestasis | 7 | 2022 | 164 | 2.530 |
Why?
|
| Cholestasis, Intrahepatic | 3 | 2022 | 57 | 1.540 |
Why?
|
| Biliary Atresia | 8 | 2018 | 215 | 1.390 |
Why?
|
| Rotavirus Infections | 5 | 2013 | 278 | 1.090 |
Why?
|
| Bilirubin | 6 | 2021 | 124 | 0.660 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 4 | 2024 | 393 | 0.550 |
Why?
|
| Premature Birth | 1 | 2021 | 415 | 0.520 |
Why?
|
| Rotavirus Vaccines | 2 | 2013 | 60 | 0.470 |
Why?
|
| Alagille Syndrome | 3 | 2022 | 51 | 0.410 |
Why?
|
| Immunization, Passive | 1 | 2013 | 120 | 0.390 |
Why?
|
| Rotavirus | 2 | 2012 | 363 | 0.370 |
Why?
|
| Bile Ducts | 1 | 2012 | 52 | 0.360 |
Why?
|
| Osteopontin | 1 | 2011 | 51 | 0.350 |
Why?
|
| ATP-Binding Cassette Transporters | 2 | 2022 | 194 | 0.340 |
Why?
|
| Liver Diseases | 4 | 2024 | 378 | 0.330 |
Why?
|
| Up-Regulation | 1 | 2011 | 829 | 0.290 |
Why?
|
| Liver | 6 | 2023 | 1761 | 0.290 |
Why?
|
| Radioactive Tracers | 1 | 2006 | 20 | 0.260 |
Why?
|
| Liver Cirrhosis | 5 | 2023 | 874 | 0.250 |
Why?
|
| Blood Specimen Collection | 1 | 2006 | 45 | 0.250 |
Why?
|
| Developmental Disabilities | 2 | 2024 | 718 | 0.250 |
Why?
|
| Infant | 16 | 2025 | 12803 | 0.240 |
Why?
|
| Carbon Isotopes | 1 | 2006 | 230 | 0.240 |
Why?
|
| Liver Transplantation | 2 | 2025 | 1096 | 0.240 |
Why?
|
| Child, Preschool | 11 | 2025 | 14375 | 0.230 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2018 | 332 | 0.210 |
Why?
|
| Cognition | 3 | 2018 | 782 | 0.210 |
Why?
|
| Male | 28 | 2025 | 62225 | 0.210 |
Why?
|
| Longitudinal Studies | 4 | 2021 | 1425 | 0.210 |
Why?
|
| Child | 13 | 2025 | 25112 | 0.200 |
Why?
|
| Sirolimus | 1 | 2025 | 224 | 0.200 |
Why?
|
| Humans | 34 | 2025 | 126134 | 0.200 |
Why?
|
| Loss of Function Mutation | 1 | 2024 | 151 | 0.200 |
Why?
|
| Female | 27 | 2025 | 68037 | 0.200 |
Why?
|
| Nutrition Assessment | 1 | 2023 | 125 | 0.190 |
Why?
|
| Homozygote | 1 | 2024 | 541 | 0.190 |
Why?
|
| Blood Glucose | 1 | 2006 | 1085 | 0.190 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2024 | 966 | 0.180 |
Why?
|
| Graft Rejection | 1 | 2025 | 555 | 0.170 |
Why?
|
| Severity of Illness Index | 3 | 2024 | 2926 | 0.170 |
Why?
|
| Immunosuppressive Agents | 1 | 2025 | 650 | 0.170 |
Why?
|
| Prospective Studies | 6 | 2024 | 6178 | 0.170 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2022 | 144 | 0.160 |
Why?
|
| Severe Combined Immunodeficiency | 2 | 2011 | 104 | 0.160 |
Why?
|
| Mice, Inbred BALB C | 2 | 2013 | 1002 | 0.160 |
Why?
|
| Failure to Thrive | 2 | 2018 | 88 | 0.160 |
Why?
|
| Liver Neoplasms | 2 | 2024 | 1351 | 0.160 |
Why?
|
| Mutation, Missense | 1 | 2024 | 889 | 0.150 |
Why?
|
| Neuropsychological Tests | 3 | 2018 | 950 | 0.150 |
Why?
|
| Animals, Newborn | 2 | 2013 | 1014 | 0.150 |
Why?
|
| Catheterization, Central Venous | 1 | 2020 | 138 | 0.140 |
Why?
|
| alpha 1-Antitrypsin Deficiency | 2 | 2015 | 43 | 0.140 |
Why?
|
| Rumination, Cognitive | 1 | 2018 | 2 | 0.140 |
Why?
|
| Catheterization, Peripheral | 1 | 2020 | 125 | 0.140 |
Why?
|
| Memory, Episodic | 1 | 2018 | 26 | 0.140 |
Why?
|
| Sarcopenia | 1 | 2018 | 54 | 0.140 |
Why?
|
| Portoenterostomy, Hepatic | 2 | 2018 | 59 | 0.140 |
Why?
|
| Etodolac | 1 | 2017 | 1 | 0.140 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2017 | 46 | 0.130 |
Why?
|
| Hyperbilirubinemia | 1 | 2017 | 41 | 0.130 |
Why?
|
| Growth Disorders | 1 | 2018 | 185 | 0.130 |
Why?
|
| Enterohepatic Circulation | 1 | 2017 | 10 | 0.130 |
Why?
|
| Gestational Age | 1 | 2021 | 1206 | 0.130 |
Why?
|
| Thinking | 1 | 2017 | 31 | 0.130 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2017 | 85 | 0.120 |
Why?
|
| Bone Density | 1 | 2018 | 351 | 0.120 |
Why?
|
| Infant, Newborn | 6 | 2021 | 8381 | 0.120 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2024 | 746 | 0.120 |
Why?
|
| Adolescent | 10 | 2025 | 19986 | 0.120 |
Why?
|
| Zonula Occludens-2 Protein | 1 | 2015 | 7 | 0.120 |
Why?
|
| Pregnancy | 2 | 2021 | 7395 | 0.120 |
Why?
|
| alpha 1-Antitrypsin | 1 | 2015 | 81 | 0.110 |
Why?
|
| Avitaminosis | 1 | 2014 | 4 | 0.110 |
Why?
|
| Hypertension, Portal | 1 | 2015 | 76 | 0.110 |
Why?
|
| Depressive Disorder | 1 | 2018 | 459 | 0.110 |
Why?
|
| Neonatal Screening | 1 | 2016 | 190 | 0.110 |
Why?
|
| Prednisolone | 1 | 2014 | 67 | 0.110 |
Why?
|
| Double-Blind Method | 4 | 2022 | 1596 | 0.100 |
Why?
|
| Methylprednisolone | 1 | 2014 | 90 | 0.100 |
Why?
|
| Memory | 1 | 2017 | 347 | 0.100 |
Why?
|
| Hypertension | 1 | 2022 | 1281 | 0.100 |
Why?
|
| Biopsy | 3 | 2023 | 1221 | 0.100 |
Why?
|
| Health Status | 1 | 2015 | 376 | 0.100 |
Why?
|
| Bias | 1 | 2013 | 135 | 0.100 |
Why?
|
| Bile Acids and Salts | 1 | 2014 | 241 | 0.100 |
Why?
|
| Disease Models, Animal | 2 | 2013 | 4433 | 0.090 |
Why?
|
| Rodent Diseases | 1 | 2011 | 15 | 0.090 |
Why?
|
| Viremia | 1 | 2011 | 130 | 0.080 |
Why?
|
| Treatment Outcome | 6 | 2024 | 12393 | 0.080 |
Why?
|
| Animals | 4 | 2024 | 33230 | 0.080 |
Why?
|
| Ornithine Carbamoyltransferase Deficiency Disease | 1 | 2009 | 35 | 0.080 |
Why?
|
| Cognition Disorders | 1 | 2013 | 542 | 0.080 |
Why?
|
| Psychiatric Status Rating Scales | 3 | 2018 | 822 | 0.070 |
Why?
|
| Lipids | 2 | 2023 | 550 | 0.070 |
Why?
|
| ROC Curve | 2 | 2023 | 566 | 0.070 |
Why?
|
| Mutation | 1 | 2021 | 5933 | 0.070 |
Why?
|
| Adult | 7 | 2024 | 30314 | 0.070 |
Why?
|
| Body Weight | 2 | 2023 | 969 | 0.070 |
Why?
|
| Global Health | 1 | 2012 | 605 | 0.060 |
Why?
|
| Infusion Pumps, Implantable | 1 | 2006 | 36 | 0.060 |
Why?
|
| Retrospective Studies | 6 | 2025 | 16831 | 0.060 |
Why?
|
| Capillaries | 1 | 2006 | 69 | 0.060 |
Why?
|
| Mice | 2 | 2013 | 17619 | 0.060 |
Why?
|
| Biomarkers | 3 | 2022 | 3149 | 0.060 |
Why?
|
| Quality of Life | 1 | 2015 | 2014 | 0.060 |
Why?
|
| Brain | 1 | 2017 | 3031 | 0.060 |
Why?
|
| Anticoagulants | 1 | 2009 | 559 | 0.060 |
Why?
|
| Depression | 1 | 2013 | 1286 | 0.050 |
Why?
|
| Thrombosis | 1 | 2009 | 497 | 0.050 |
Why?
|
| Cohort Studies | 3 | 2022 | 4894 | 0.050 |
Why?
|
| Regression Analysis | 2 | 2018 | 762 | 0.050 |
Why?
|
| R-SNARE Proteins | 1 | 2024 | 22 | 0.050 |
Why?
|
| Incidence | 1 | 2012 | 3193 | 0.050 |
Why?
|
| Young Adult | 4 | 2024 | 9635 | 0.050 |
Why?
|
| Sugars | 1 | 2023 | 18 | 0.050 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2011 | 1158 | 0.050 |
Why?
|
| Mice, Knockout | 1 | 2011 | 3716 | 0.050 |
Why?
|
| Multivariate Analysis | 2 | 2018 | 1349 | 0.050 |
Why?
|
| Vesicular Transport Proteins | 1 | 2024 | 137 | 0.050 |
Why?
|
| Telomere | 1 | 2024 | 211 | 0.050 |
Why?
|
| Endoglin | 1 | 2022 | 30 | 0.050 |
Why?
|
| Matrix Metalloproteinase 7 | 1 | 2022 | 25 | 0.050 |
Why?
|
| Losartan | 1 | 2022 | 34 | 0.050 |
Why?
|
| Interleukin-8 | 1 | 2022 | 203 | 0.050 |
Why?
|
| Chronic Disease | 2 | 2018 | 1179 | 0.040 |
Why?
|
| Glomerular Filtration Rate | 1 | 2024 | 494 | 0.040 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2022 | 124 | 0.040 |
Why?
|
| Fibrosis | 1 | 2022 | 394 | 0.040 |
Why?
|
| Risk Factors | 2 | 2012 | 10374 | 0.040 |
Why?
|
| Umbilical Veins | 1 | 2020 | 64 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2006 | 2877 | 0.040 |
Why?
|
| Drosophila | 1 | 2024 | 782 | 0.040 |
Why?
|
| Alleles | 1 | 2024 | 1611 | 0.040 |
Why?
|
| Catheterization | 1 | 2020 | 232 | 0.040 |
Why?
|
| Cephalometry | 1 | 2018 | 43 | 0.040 |
Why?
|
| Absorptiometry, Photon | 1 | 2018 | 195 | 0.040 |
Why?
|
| Drosophila Proteins | 1 | 2024 | 760 | 0.030 |
Why?
|
| Disease Progression | 1 | 2024 | 2110 | 0.030 |
Why?
|
| Motor Skills | 1 | 2018 | 76 | 0.030 |
Why?
|
| Observational Studies as Topic | 1 | 2018 | 98 | 0.030 |
Why?
|
| Cues | 1 | 2018 | 98 | 0.030 |
Why?
|
| Prevalence | 1 | 2024 | 2571 | 0.030 |
Why?
|
| False Positive Reactions | 1 | 2017 | 134 | 0.030 |
Why?
|
| Reference Values | 1 | 2018 | 678 | 0.030 |
Why?
|
| Blood Pressure | 1 | 2022 | 1302 | 0.030 |
Why?
|
| Postoperative Care | 1 | 2018 | 303 | 0.030 |
Why?
|
| Vulnerable Populations | 1 | 2018 | 143 | 0.030 |
Why?
|
| Monitoring, Physiologic | 1 | 2018 | 370 | 0.030 |
Why?
|
| Risk | 1 | 2018 | 723 | 0.030 |
Why?
|
| Child Development | 1 | 2018 | 265 | 0.030 |
Why?
|
| Students | 1 | 2018 | 248 | 0.030 |
Why?
|
| Jaundice | 1 | 2015 | 27 | 0.030 |
Why?
|
| Algorithms | 1 | 2022 | 1639 | 0.030 |
Why?
|
| National Institute of Diabetes and Digestive and Kidney Diseases (U.S.) | 1 | 2014 | 8 | 0.030 |
Why?
|
| North America | 1 | 2015 | 250 | 0.030 |
Why?
|
| International Cooperation | 1 | 2015 | 156 | 0.030 |
Why?
|
| Brain Mapping | 1 | 2017 | 384 | 0.030 |
Why?
|
| Vitamin K | 1 | 2014 | 34 | 0.030 |
Why?
|
| Vitamin E | 1 | 2014 | 62 | 0.030 |
Why?
|
| Vitamin A | 1 | 2014 | 57 | 0.030 |
Why?
|
| Europe | 1 | 2015 | 353 | 0.030 |
Why?
|
| Phenotype | 1 | 2024 | 4313 | 0.030 |
Why?
|
| Vitamins | 1 | 2014 | 108 | 0.030 |
Why?
|
| Placebos | 1 | 2014 | 224 | 0.030 |
Why?
|
| Surveys and Questionnaires | 2 | 2015 | 3895 | 0.030 |
Why?
|
| Learning | 1 | 2017 | 356 | 0.030 |
Why?
|
| Social Behavior | 1 | 2015 | 220 | 0.030 |
Why?
|
| Middle Aged | 2 | 2024 | 27402 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2024 | 3260 | 0.020 |
Why?
|
| Vitamin D | 1 | 2014 | 174 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2018 | 1179 | 0.020 |
Why?
|
| Reaction Time | 1 | 2013 | 157 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2014 | 523 | 0.020 |
Why?
|
| Cholesterol | 1 | 2015 | 547 | 0.020 |
Why?
|
| Drainage | 1 | 2014 | 251 | 0.020 |
Why?
|
| Emotions | 1 | 2015 | 355 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2017 | 1823 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2014 | 677 | 0.020 |
Why?
|
| Comorbidity | 1 | 2017 | 1525 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2016 | 2038 | 0.020 |
Why?
|
| Dietary Supplements | 1 | 2014 | 437 | 0.020 |
Why?
|
| Logistic Models | 1 | 2015 | 1739 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2014 | 1475 | 0.020 |
Why?
|
| Obesity | 1 | 2022 | 2328 | 0.020 |
Why?
|
| Diarrhea, Infantile | 1 | 2010 | 31 | 0.020 |
Why?
|
| Dehydration | 1 | 2010 | 40 | 0.020 |
Why?
|
| Virus Shedding | 1 | 2010 | 75 | 0.020 |
Why?
|
| Diarrhea | 1 | 2011 | 304 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2018 | 3422 | 0.020 |
Why?
|
| Compartment Syndromes | 1 | 2009 | 29 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 5107 | 0.020 |
Why?
|
| Enoxaparin | 1 | 2009 | 41 | 0.020 |
Why?
|
| Sinus Thrombosis, Intracranial | 1 | 2009 | 48 | 0.020 |
Why?
|
| Time Factors | 1 | 2018 | 6030 | 0.020 |
Why?
|
| DNA, Viral | 1 | 2010 | 449 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 2010 | 588 | 0.020 |
Why?
|
| Stem Cell Transplantation | 1 | 2010 | 225 | 0.020 |
Why?
|
| Decision Making | 1 | 2013 | 665 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2015 | 3307 | 0.020 |
Why?
|
| RNA, Viral | 1 | 2010 | 511 | 0.020 |
Why?
|
| Venous Thrombosis | 1 | 2009 | 167 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 1236 | 0.020 |
Why?
|
| Feces | 1 | 2010 | 702 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2017 | 3593 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2010 | 1739 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2011 | 1706 | 0.010 |
Why?
|
| United States | 1 | 2014 | 11187 | 0.010 |
Why?
|